Pfizer Japan Spinout RaQualia Cuts Another Deal With Korea's CJ CheilJedang
This article was originally published in PharmAsia News
Executive Summary
SEOUL - In a follow-up to a memorandum of understanding signed in 2010, CJ CheilJedang Corp. signed an agreement with RaQualia Pharm Inc. for exclusive rights to develop, manufacture and commercialize RaQualia's 5-HT4 partial agonist (RQ-0010) in South Korea, China, Taiwan, India and Southeast Asia